London-based Livanova plc has agreed to acquire Tandemlife for $200 million up front and up to an additional $50 million in regulatory milestones. The Pittsburgh-based startup has an FDA cleared and CE marked short-term extracorporeal circulatory support platform, which it said is the world's first. Tandemlife's four products are for hospital use and are designed around a single pump and controller. The deal is slated to close during the first half of this year.

Baltimore-based startup Eneura Inc. has raised a $17 million series D round to market its handheld transcranial magnetic stimulation device. Last fall, the FDA cleared the daily, single use device, known as the sTMS mini, for migraine prevention. That makes it the only treatment – drug or device – that's been given a nod from the regulator for both acute migraine treatment and prevention.